儿科大脑的OV调节器 时间:当前状态,组合策略,局限性和未来方向
Konstantinos Vazaios1, Ronja E van Berkum1, Friso G Calkoen1
1Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
International journal of molecular sciences
|May 11, 2024
概括
瘤病毒 (OVs) 通过向癌细胞和刺激抗瘤免疫力,显示出治疗儿科脑瘤 (PBTs) 的前景. 本综述探讨了OV如何改变瘤免疫微环境 (TIME),并讨论了PBT中OV治疗的挑战和未来方向.
科学领域:
- 瘤治疗性病毒疗法
- 免疫瘤学 免疫瘤学
- 儿科神经瘤学 儿科神经瘤学
背景情况:
- 儿科大脑瘤 (PBT) 经常呈现出"冷"的瘤免疫微环境 (TIME),阻碍了免疫治疗的有效性.
- 瘤病毒 (OV) 选择性地感染和溶解瘤细胞,可能逆转免疫抑制.
- 卵巢病毒可以刺激本地和全身的抗癌免疫反应.
研究的目的:
- 审查OV治疗对PBT的时间的影响.
- 探索涉及OV和其他PBT免疫疗法的组合疗法.
- 确定在PBT中OV治疗的局限性和未来方向.
主要方法:
- 在PBT中对OV进行的临床前和临床研究的文献综述.
- 对OV诱导的瘤免疫微环境 (TIME) 变化的分析.
- 结合策略和治疗障碍的检查.
主要成果:
- 卵巢病毒可以诱导促炎性免疫反应,有可能将"冷"的时间转化为"热"的时间.
- 与OV和其他免疫疗法的组合疗法在增强抗瘤活性方面表现有前途.
- 了解OV对不同类型的TIME细胞的影响对于优化治疗至关重要.
结论:
- OVs代表了PBT的一个有前途的治疗策略,特别是由于它们的免疫调节作用.
- 克服转化挑战和先前存在的免疫等局限性是有效的OV治疗的关键.
- 对OV介导的时间调节和组合策略进行进一步的研究是对PBT治疗的必要.
更多相关视频
08:58A Benchtop Approach to the Location Specific Blood Brain Barrier Opening using Focused Ultrasound in a Rat Model
Published on: June 13, 2020
4.6K
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
3.6K
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
